ClinicalTrials.gg
Not yet recruitingNCT06965868PHASR-PPUpdated May 11, 2025

Role of the Blood-Brain Barrier in Stress Resilience: Investigating New Pathways Towards Pharmacological Augmentation of Stress Resilience

An interventional study of Metformin and Placebo in Stress Resilience, Blood-Brain Barrier Integrity and Mental Health, sponsored by Leibniz-Institut für Resilienzforschung (LIR) gGmbH. Not yet recruiting at 3 sites in 3 countries. Open to participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-11.

Sponsored by Leibniz-Institut für Resilienzforschung (LIR) gGmbH · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Psychological Well-Being with a site in Germany — 19 open to participants now, 22 under way, none of them phase 3. Psychological Well-Being · Germany.

Planned enrollment
21st of 37
122 · median 160
Started
2025
with 3 others
No phase
35 of 56
12 open now
Primary completion
2027-02
later than 13 of 21 live
Registered
45th of 56
by date

Among the 56 studies in Psychological Well-Being with a site in Germany, this one is the 21st largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2025, is one of 35 with no phase, reaches primary completion later than 13 of the 21 other live ones, and was the 45th registered.

Psychological Well-Being

2,208 studies on the registry are indexed under Psychological Well-Being; 730 are open to participants now.

Browse Psychological Well-Being studies →

Open to participants now

19 of the 56 studies in Psychological Well-Being with a site in Germany are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 403 Psychological Well-Being studies recruiting now, 223 (55%) set no upper age limit and 155 (38%) stop at 75 or younger; 121 take children under 18; 206 take healthy volunteers.

This study: 18 Years to 25 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Psychological Well-Being with a site in Germany, or all of them as a file.
02

Study summary

The goal of this clinical trial is to better understand the relationship between blood-brain barrier (BBB) function and stress resilience and to investigate a potential causal role for BBB function in stress resilience in humans. The researchers will look for particpants that are young adults to answer the following questions to reach our goal:

  • Is better BBB integrity, measured with neuroimaging, associated with better stress resilience in the short term and in the long term?
  • Does the administration of Metformin improve BBB integrity?
  • Is improved BBB integrity a possible link between Metformin and better short- and long-term stress resilience?

The participants will do the following during our study:

  • Participants will fill in online surveys on stressor exposure and mental health once every four weeks over 36 weeks
  • Participants will visit the study site 4 times:
  • The first time for a screening process which includes questionnaires, a medical exam and a blood sample.
  • The next 2 visits will include a blood sample, a medical exam, an MRI scan and a list of questionnaires
  • The last visit will include another blood sample, a medical exam and a list of questionnaires.
  • Between visit 2 and 3, the participant will take either Metformin or Placebo
Read the detailed description

STUDY DESIGN

Prospective, randomized, parallel-group, placebo-controlled, double-blind, multi-center experimental study to investigate the relationship between individual variation in BBB integrity and individual variation in stress resilience in young healthy adult participants at risk for stress-related mental health problems, making use of a 12-week oral administration of Metformin (850 mg twice daily at full dose) as an experimental tool to enhance individual variation in BBB integrity (experimental manipulation). The duration of the study for a participant will be 36 weeks in total. Participants will be assessed at three different study sites (i.e. Mainz, Germany, Zürich, Switzerland, Warsaw, Poland).

The study is divided into 10 phases of 4 weeks each, and has the following study flow and intervention scheme:

  • Screening phase: Potential participants will be screened and assessed for eligibility. If eligible, informed consent will be obtained.
  • Time point T0, week 1 - Baseline: Medical exam, blood sampling, randomization, neuroimaging, questionnaires, distribution of study drug. Start of the online monitoring of stressor exposure and mental health, which participants will perform every four weeks (time points T0 to T9), throughout the study.
  • Time points T0 to T3, week 1 - 12 - Experimental Manipulation phase: Four weeks of dose increase (T0 to T1), i.e., first and second week 500 mg once daily, third and fourth week 500mg twice daily. Full-dose administration (850 mg twice daily) for eight weeks (T1 to T3).
  • Time point T3, week 12 - End of Experimental Manipulation: Medical exam, blood sampling, neuroimaging and questionnaires. Adverse Event (AE) monitoring.
  • Time points T4 to T9, week 12 to 36 - Follow-up: separated into early (T4 to T6) and late (T7 to T9) follow-up period.
  • Time point T9, week 36 - End of follow-up: Medical exam, blood sampling, questionnaires and AE monitoring.

OUTCOME MEASURES

Stress resilience is quantified as inverse stressor reactivity (SR). Short-term stress resilience is the average inverse SR score in the 12 weeks after the Experimental Manipulation phase (online monitoring time points T4 to T6). Long-term stress resilience is the average inverse SR score in the 24 weeks after the Experimental Manipulation phase (time points T4 to T9). SR is calculated as an individual's deviation (residual) from a regression of mental health problems [z-standardized sum score of anxiety and depression symptoms, as assessed with the Patient Health Questionnaire - Anxiety and Depression Scale (PHQ-ADS) during online monitoring] on stressor exposure [z-scored sum of occurrences of all daily hassles (DHs), as assessed with the Mainz Inventory of Microstressors (MIMIS) during online monitoring] in the study sample.

Whole-brain BBB integrity is quantified as inverse whole-brain water exchange rate (kw) from blood to brain tissue (BBB permeability), as assessed with neuroimaging before (time point T0) and after the Experimental Manipulation phase (time point T3).

CALCULATING THE SR SCORE

To build the SR score, first, the stressor exposure score E is calculated for every four-weekly monitoring time point after T0 (T1 to T9) as the z-scored sum of occurrences of all daily hassles (DHs), assessed with the MIMIS. Life event (LE) occurrence, assessed with a life-events list, is expected to be less frequent than DH occurrence but, if reported, expected to correlate with DH occurrence. This will be used to corroborate the validity of the DH-based E score. For each monitoring time point, a mental health problem score P is also calculated as the z-standardized sum score of anxiety and depression symptoms, as assessed with the PHQ-ADS. To quantify how strongly participants' mental health problems relate to stressor exposure, the researchers then calculate the relationship between E and P in the analysis sample for a given study phase by fitting a linear mixed model to predict P by E over all included participants and monitoring time points Tx, with random slopes and intercepts for participants. The E-P regression line is then determined by the fixed effect estimates for the EP slope and intercept and serves as the normative E-P relationship for the analysis sample over the study phase of interest. The form of regression that explains most variance in P (linear or quadratic) will be used. At each Tx, the participants' individual E scores will be entered into the normative E-P line equation, giving us their expected P score when assuming normal stressor reactivity. The SR score is the individual's average residual onto the regression line for the study phase of interest.

MEASURING BBB INTEGRITY

A pseudo-continuous ASL (pCASL) MRI sequence will be used to estimate BBB permeability. By reading out pCASL signals at different post-labeling delays (PLD) under different diffusion gradients, perfusion signals in capillary and brain tissues can be reliably estimated and subsequently fitted into a model to estimate the water exchange rate (kw) from blood to brain tissue, an index quantifying BBB permeability. Analysis will use a toolbox provided by the sequence developer (http://loft-lab.org/index-5.html) and includes image reconstruction, preprocessing (motion-correction, coregistration, skull-stripping), and kw modeling. Whole-brain averaged kw values quantifying overall BBB permeability will be calculated. BBB integrity is quantified as inverse permeability.

ADDITIONAL OUTCOME MEASURES

For additional exploratory analyses, blood samples will be taken and used to determine blood-based molecular and cellular markers of immune system, metabolic, and BBB function (including proteins, peptides, RNAs, metabolites). In these additional analyses, BBB integrity will be assessed using both blood-based biomarkers and regional neuroimaging measures (esp. of hippocampus, ventral striatum, and prefrontal cortex), and the association of immunological covariates with BBB integrity and stress resilience will also be considered. Further, socio-demographic and psycho-social variables will be assessed via questionnaire and tested for their association with BBB integrity and stress resilience.

SAMPLE SIZE

Because the association of BBB function in stressor-exposed individuals at risk for stress-related mental health problems with stress resilience (inverse SR score) has never been investigated, the researchers base their power calculation for the primary endpoint on the sensitivity to detect a medium effect size of Cohen's d = 0.3. With a power of 0.8, a two-sided alpha-level of 0.05, and a linear mixed model with eight predictor variables (3 variables of interest and 5 covariates), n=109 participants are needed. Taking into account 10% attrition, our aim is to recruit a total number of 122 participants (61 in each group).

STRATEGIES FOR DATA HANDLING AND THE DISSEMINATION OF RESULTS

Data collection and data management will be conducted in compliance with the principles of the declaration of Helsinki (1996) and relevant national and regional regulations and will only follow study protocols approved by the regional ethics committee at each partner site/country. The investigator at each partner site will be responsible for data management in accordance with these principles. The investigators will collect and process MRI imaging data (digital: DICOM), biosamples (blood), biological data from the analysis of biosamples (digital: concentrations of plasma proteins/peptides, RNAs, metabolites, and other molecules), and computerized (digital: offline and online collection) and paper-and-pencil (analogue) questionnaire and interview data. Data will be made findable with a study description and metadata following fairsharing.org conventions. Open accessibility and data re-use are complicated by the sensitive personal nature of most data and the principled non-anonymizability esp. of MRI data. Participant consent forms will permit sharing of pseudonymized data and biosamples among the sites and with collaborators within the European Union and countries with an adequacy decision under Article 45 GDPR, under the supervision of a Data Use and Access Committee (DUAC). All anonymized data will be made openly accessible through public depositories (in particular, OSF) upon publication or at latest two years after the termination of the project and will remain accessible for at least ten years upon completion of the study.

03

Conditions studied

  • Stress Resilience
  • Blood-Brain Barrier Integrity
  • Mental Health

Keywords

  • Stress Resilience
  • Blood Brain Barrier
  • Emerging Adults
  • BBB integrity
  • at-risk
  • prospective
  • placebo-controlled
  • University Students
  • Metformin
04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria: (participants meeting all of the following criteria will be considered for enrollment in the study)

  1. Absence of mental disorder diagnosis.
  2. University students.
  3. GHQ-28 > 20
  4. Three or more adverse life events acc. to LE list in the past
  5. Beck Depression Inventory (BDI) ≤ 14 \& Columbia-Suicide Severity Rating Scale (C-SSRS) ≤ 1. Thereby concurrent depression and suicidality are excluded.
  6. Age 18 to 25 years
  7. Ability of participant to understand character and individual consequences of the study ( Folstein > 28)
  8. Signed and dated of participant

Exclusion criteria: (participants presenting 1 of the following criteria will not be enrolled in the study)

  1. Life-time and current diagnosis of any severe mental disorder determined by M.I.N.I. diagnostic interview.
  2. Known history of brain injuries or neurodevelopmental disorder.
  3. Evidence of neurodegenerative disorder (e.g., Parkinson).
  4. Multimorbidity or significant organ (esp. liver or renal) dysfunction or manifest diabetes or substance abuse (esp. alcohol).
  5. to metformin such as renal insufficiency (Creatinin-Clearance\< 60ml/min), recent (\<3 month) ischemic events (e.g. myocardial infarction or stroke).
  6. Women of childbearing age, who do not practice a medically accepted (i.e., systematic contraceptives, diaphragm, condoms with spermicide, sexual abstinence) during the study and during a 2 years post-study period and who do not present a negative pregnancy test (serum or urine).
  7. History of to the study drug, to any drug with similar chemical structure, or to any present in the pharmaceutical form of the study drug.
  8. Diabetes type 2 (would result in interference with the experimental manipulation)
  9. Participation in other studies employing a drug during the present study or within the last three months.
  10. Current use of antidiabetic, weight-loss, or psychoactive medication or substances.
  11. Pacemaker, implanted medical pumps, implanted cardiac catheters or acute or unstable heart disease (angina pectoris).
  12. Intracranial implant (aneurysm clips, shunts, stimulators, cochlear implants or electrodes) or other metallic objects inside or near the head (mouth excluded) that cannot be removed.
  13. Claustrophobia or another contraindication to MRI.
  14. Insufficient German language skills.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
122 participants (estimated)

Study arms

  • Other
    Metformin

    Metformin is used as an experimental tool in the attempt to enhance inter-individual variation in Blood-Brain Barrier integrity in the study sample.

    Drug: Metformin

  • Placebo comparator
    Placebo

    Placebo will be given as a control intervention.

    Drug: Placebo

Interventions

  • The Metformin intervention will be self-administred capsules, taken during a 12-week period: Four weeks of dose increase; first and second week 500 mg once daily, third and fourth week 500mg twice daily. Full-dose administration (850 mg twice daily) for eight weeks.

  • DrugPlacebo

    This intervention will be self-administered placebo capsules

06

What researchers measure

Primary outcomes

  1. Average stressor reactivity (SR) score in the 'early follow-up' study phase

    SR is the residual deviation of an individual from the sample's normative relation between stressor exposure (E) and mental health problems (P). A positive residual indicates more mental health problems than expected based on the normative E-P relationship. A negative residual (negative SR score) indicates less mental health problems than expected. Hence, SR is an inverse continuous expression of an individual's resilience.

    Time frame: From week 13 after enrollment (T4) until week 24 after enrollment (T6)

Secondary outcomes

  1. Whole-brain Blood-Brain Barrier Integrity, assessed with neuroimaging at T0 and T3

    A pseudo-continuous ASL (pCASL) MRI sequence will be used to estimate BBB integrity (inverse whole-brain-averaged water exchange rate (kw) from blood to brain tissue).

    Time frame: Week 1 after enrollment (T0), before the Experimental Manipulation phase, and week 12 after enrollment (T3), at the end of the Experimental Manipulation phase

Other outcomes

  1. Average stressor reactivity (SR) score in the 'whole follow-up' study phase

    SR is the residual deviation of an individual from the sample's normative relation between stressor exposure (E) and mental health problems (P). A positive residual indicates more mental health problems than expected based on the normative E-P relationship. A negative residual (negative SR score) indicates less mental health problems than expected. Hence, SR is an inverse continuous expression of an individual's resilience.

    Time frame: From week 13 (T4) after enrollment until week 36 after enrollment (T9).

07

Study locations

3 sites
08

References and documents

Publications

  • Kalisch R, Muller MB, Tuscher O. A conceptual framework for the neurobiological study of resilience. Behav Brain Sci. 2015;38:e92. doi: 10.1017/S0140525X1400082X. Epub 2014 Aug 27. PubMed 25158686 ↗
  • Cathomas F, Holt LM, Parise EM, Liu J, Murrough JW, Casaccia P, Nestler EJ, Russo SJ. Beyond the neuron: Role of non-neuronal cells in stress disorders. Neuron. 2022 Apr 6;110(7):1116-1138. doi: 10.1016/j.neuron.2022.01.033. Epub 2022 Feb 18. PubMed 35182484 ↗
  • Vennin C, Hewel C, Todorov H, Wendelmuth M, Radyushkin K, Heimbach A, Horenko I, Ayash S, Muller MB, Schweiger S, Gerber S, Lutz B. A Resilience Related Glial-Neurovascular Network Is Transcriptionally Activated after Chronic Social Defeat in Male Mice. Cells. 2022 Oct 27;11(21):3405. doi: 10.3390/cells11213405. PubMed 36359800 ↗
  • Shao X, Ma SJ, Casey M, D'Orazio L, Ringman JM, Wang DJJ. Mapping water exchange across the blood-brain barrier using 3D diffusion-prepared arterial spin labeled perfusion MRI. Magn Reson Med. 2019 May;81(5):3065-3079. doi: 10.1002/mrm.27632. Epub 2018 Dec 18. PubMed 30561821 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data will be made findable with a study description and metadata following fairsharing.org conventions. Data will be made interoperable by using common standardized formats (in particular, BIDS for MRI) and a detailed codebook. Open accessibility and data re-use are complicated by the sensitive personal nature of most data and the principled non-anonymizability esp. of MRI data. Participant consent forms will permit sharing of pseudonymized data and biosamples among the sites and with collaborators under the supervision of a Data Use and Access Committee (DUAC). All anonymized data will be made openly accessible through public depositories (in particular, OSF).

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: All anonymized data will be made openly accessible through public depositories (in particular, OSF) upon publication or at latest two years after the termination of the project and will remain accessible for at least ten years upon completion of the study.

Access criteria: Collaborators can get access to the pseudonymized data under the supervision of a Data Use and Access Committee (DUAC). All anonymized data will be made openly accessible through public depositories (in particular, OSF).

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Feb 2027, 20 months later.

Of 1,274 non-industry interventional studies with no phase under Psychological Well-Being, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 34. This study's planned 20 months is above that.

Counting every sponsor, half of 1,317 studies reached it within 16 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
May 11, 2025
StartEst.
Jun 2025
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
May 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06965868
Lead sponsor
Leibniz-Institut für Resilienzforschung (LIR) gGmbH
Collaborators
University of Latvia, University of Zurich, Johannes Gutenberg University Mainz, University of Warsaw
Responsible party
Raffael Kalisch, PhD (Prof. Dr. Raffael Kalisch, Leibniz-Institut für Resilienzforschung (LIR) gGmbH) — Principal investigator
First posted
May 11, 2025
Start date
Jun 2025 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
May 11, 2025

Study contacts

Frédérique M.W Maas, MSc
Contact
Frederique.Maas@lir-mainz.de
+49 155 1060 7971
Raffael Kalisch, Prof. Dr.
Contact
raffael.kalisch@lir-mainz.de
+49 (0)6131 178419
Raffael Kalisch, Prof. Dr.
principal investigator · Leibniz Institute for Resilience Research gGmbH (LIR)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion